<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904500</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13040497</org_study_id>
    <nct_id>NCT01904500</nct_id>
  </id_info>
  <brief_title>Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida</brief_title>
  <official_title>Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      Obesity has become an increasingly prevalent public health problem in the United States,
      reaching epidemic proportions. According to 2009 CDC epidemiologic data on obesity in the
      United States, 35.7% of the United States population is considered overweight or obese.
      Currently, on the review of the literature, over 20% of pregnancies in this country are
      complicated by maternal obesity. Obesity has been well demonstrated to be correlated with
      numerous adverse pregnancy outcomes such hypertensive disorders of pregnancy, gestational
      diabetes, and increased rates of operative delivery. Moreover, obesity, irrespective of
      pregnancy, has been demonstrated to be an independent risk factor for the development of
      postoperative surgical site infections. Development of such infections can have both
      consequential long-term medical sequelae for patients and economic impacts on the health care
      system at large. Cefazolin, a first generation hydrophilic cephalosporin whose clearance is
      exclusively mediated via the kidneys unchanged, is used as pre-operative antibiotic
      prophylaxis for cesarean deliveries. The current accepted standard of care is to administer 2
      grams of cefazolin within 60 minutes of skin incision. Studies of drug concentrations of
      cephalosporins for pre-operative antibiotic prophylaxis in obese bariatric patients have
      shown that therapeutic concentrations may not be achieved in both tissue and plasma. Limited
      data exist in pregnancy. Therefore, it is the goal of this study to investigate whether obese
      patients presenting for cesarean delivery require an increased dosing amount of pre-operative
      antibiotic prophylaxis. This study will randomized women with a pre-pregnancy body mass index
      of 30 kg/m2 or more who are presenting for their scheduled cesarean delivery to receive
      either 2 grams or 3 grams of cefazolin for pre-operative antibiotic prophylaxis. By drawing
      blood at specific time points in the peri-operative period and extracting adipose tissue
      samples during cesarean delivery, this study will investigate the pharmacokinetics of
      cefazolin in both the plasma and tissues of the obese gravida.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma area under the curve (AUC) of cefazolin</measure>
    <time_frame>Within the first 8 hours after skin incision</time_frame>
    <description>The primary aim of this study will be to evaluate the plasma area under the curve (AUC) of cefazolin in both the 2 grams and 3 grams groups. Blood samples will be obtained prior to administration of cefazolin and then 15 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 4 hours, 6 hours and 8 hours from administration of cefazolin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue concentrations of cefazolin</measure>
    <time_frame>Adipose tissue samples will be assessed at time of skin incision, hysterotomy closure and then fascial closure.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Within the first 8 hours after skin incision</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Clearance (Cl)</measure>
    <time_frame>Within the first 8 hours after skin incision</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>Within the first 8 hours after skin incision</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute drug concentrations in plasma and tissue</measure>
    <time_frame>Within the first 8 hours after skin incision</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue to Plasma (T/P) Drug Concentration Ratios</measure>
    <time_frame>Within the first 8 hours after skin incision</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical site infection fo any type</measure>
    <time_frame>Participants will be followed for the duration of their hospital stay and will be called at 6 weeks from surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cord blood concentration</measure>
    <time_frame>At time of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine drug concentration</measure>
    <time_frame>8 hours</time_frame>
    <description>Samples to be obtained up to 8 hours post cesarean delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Obesity</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Cefazolin 2 grams</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin 3 grams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-operative cefazolin</intervention_name>
    <arm_group_label>Cefazolin 2 grams</arm_group_label>
    <arm_group_label>Cefazolin 3 grams</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) greater than 30kg/m2

          -  Those women having scheduled primary or repeat cesarean delivery

        Exclusion Criteria:

          -  Type 1 and Type 2 Insulin Dependent Diabetes Mellitus

          -  Autoimmune disease, including systemic lupus erythematosus

          -  History of chronic renal disease

          -  Those using chronic corticosteroids

          -  Those with a history of a previous wound breakdown

          -  Those who have an allergy to cephalosporins whose reaction includes anaphylaxis,
             urticaria or other systemic consequences

          -  Those who are unable to receive their antibiotics in a timely fashion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Fellow, Division of Maternal-Fetal Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Magee-Women's Hospital/University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief. 2012 Jan;(82):1-8.</citation>
    <PMID>22617494</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011 Jun;117(6):1472-83. doi: 10.1097/AOG.0b013e3182238c31.</citation>
    <PMID>21606770</PMID>
  </reference>
  <reference>
    <citation>Dinsmoor MJ, Gilbert S, Landon MB, Rouse DJ, Spong CY, Varner MW, Caritis SN, Wapner RJ, Sorokin Y, Miodovnik M, O'Sullivan MJ, Sibai BM, Langer O; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery. Obstet Gynecol. 2009 Oct;114(4):752-6. doi: 10.1097/AOG.0b013e3181b8f28f.</citation>
    <PMID>19888031</PMID>
  </reference>
  <reference>
    <citation>Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007 Aug;27(8):1081-91. Review.</citation>
    <PMID>17655508</PMID>
  </reference>
  <reference>
    <citation>Pevzner L, Swank M, Krepel C, Wing DA, Chan K, Edmiston CE Jr. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011 Apr;117(4):877-82. doi: 10.1097/AOG.0b013e31820b95e4.</citation>
    <PMID>21422859</PMID>
  </reference>
  <reference>
    <citation>Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):89-96. Review.</citation>
    <PMID>7587056</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009 Mar;113(3):675-82. doi: 10.1097/AOG.0b013e318197c3b6. Review.</citation>
    <PMID>19300334</PMID>
  </reference>
  <reference>
    <citation>Ho VP, Nicolau DP, Dakin GF, Pomp A, Rich BS, Towe CW, Barie PS. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012 Feb;13(1):33-7. doi: 10.1089/sur.2010.097. Epub 2012 Feb 8.</citation>
    <PMID>22316145</PMID>
  </reference>
  <reference>
    <citation>van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, van Ramshorst B, Vlaminckx B, Deneer VH, Knibbe CA. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011 Oct;67(10):985-92. doi: 10.1007/s00228-011-1048-x. Epub 2011 Apr 16.</citation>
    <PMID>21499760</PMID>
  </reference>
  <reference>
    <citation>Toma O, Suntrup P, Stefanescu A, London A, Mutch M, Kharasch E. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg. 2011 Oct;113(4):730-7. doi: 10.1213/ANE.0b013e31821fff74. Epub 2011 Jun 3.</citation>
    <PMID>21642605</PMID>
  </reference>
  <reference>
    <citation>Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am. 2003 Sep;17(3):599-613. Review.</citation>
    <PMID>14711079</PMID>
  </reference>
  <reference>
    <citation>Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989 Oct;106(4):750-6; discussion 756-7.</citation>
    <PMID>2799651</PMID>
  </reference>
  <reference>
    <citation>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.</citation>
    <PMID>10196487</PMID>
  </reference>
  <reference>
    <citation>Allegaert K, van Mieghem T, Verbesselt R, de Hoon J, Rayyan M, Devlieger R, Deprest J, Anderson BJ. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol. 2009 Feb;200(2):170.e1-7. doi: 10.1016/j.ajog.2008.08.067. Epub 2008 Nov 11.</citation>
    <PMID>19006783</PMID>
  </reference>
  <reference>
    <citation>Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet. 1987 Feb;12(2):136-44.</citation>
    <PMID>3829560</PMID>
  </reference>
  <reference>
    <citation>Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008 Jun;36(6):1088-96. doi: 10.1124/dmd.107.019125. Epub 2008 Mar 13.</citation>
    <PMID>18339814</PMID>
  </reference>
  <reference>
    <citation>Sakurai Y, Motohashi H, Ogasawara K, Terada T, Masuda S, Katsura T, Mori N, Matsuura M, Doi T, Fukatsu A, Inui K. Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm Res. 2005 Dec;22(12):2016-22. Epub 2005 Nov 1.</citation>
    <PMID>16247710</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>August 15, 2014</last_update_submitted>
  <last_update_submitted_qc>August 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Omar M Young, MD</investigator_full_name>
    <investigator_title>Clinical Fellow, Division of Maternal-Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>Cesarean delivery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

